# A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants

> **NCT04154800** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 114 (actual)

## Conditions studied

- Health Participants

## Interventions

- **DRUG:** BMS-986209
- **OTHER:** BMS-986209 Placebo
- **DRUG:** Itraconazole
- **DRUG:** Diltiazem

## Key facts

- **NCT ID:** NCT04154800
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-06
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-08-31
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2022-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04154800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04154800, "A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04154800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*